Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

7,791 total articles

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio announced its plans to initiate Phase 3 clinical trials of verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) starting Q1 2027, following positive Phase 2 trial results that showed significant efficacy improvements. The company reported strong top-line data from the VALIANT trial in severe asthma and reinf…

USA Rare Earth Achieves Major Operational and Strategic Milestone with Commissioning of Phase 1a Magnet Production at Stillwater Facility

USA Rare Earth Achieves Major Operational and Strategic Milestone with Commissioning of Phase 1a Magnet Production at Stillwater Facility

USA Rare Earth (USAR) has successfully commissioned its commercial magnet production line at the Stillwater, Oklahoma facility, enabling shipment of sintered neodymium-iron-boron permanent magnets starting in Q2 2026. The company expects to ramp Phase 1a capacity to 600 metric tons per annum by Q4 2026 and reach 1,200 mtpa with Phase 1b by Q1 2027,…

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Gain Therapeutics reported its financial results for Q4 and full-year 2025, highlighting significant progress with its lead drug candidate GT-02287 for Parkinson's disease. Positive Phase 1b clinical data indicates disease-modifying potential, with stable clinical scores and biomarker improvements. The company plans to initiate Phase 2 trials in th…

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Acumen Pharmaceuticals reported financial results for 2025, highlighting progress on its lead Alzheimer's treatment candidate sabirnetug (ACU193), including anticipation of topline Phase 2 ALTITUDE-AD study results in late 2026 and expected IND filing for its Enhanced Brain Delivery program in mid-2027. The company secured $35.75 million in private…

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics reported strong progress in its Phase 2 clinical programs, including near-completion of enrollment for the schizophrenia ZEPHYR trial and completion of enrollment for the autism spectrum disorder IRIS trial, with topline data expected in Q3 2026. The company received FDA Fast Track designation for its Alzheimer's disease psych…

Sportradar Expands Partnership with Hard Rock Bet, Adding Official Data from the PGA TOUR and Ultimate Fighting Championship

Sportradar Expands Partnership with Hard Rock Bet, Adding Official Data from the PGA TOUR and Ultimate Fighting Championship

Sportradar has deepened its multi-year partnership with Hard Rock Bet in the U.S. by integrating official PGA TOUR and Ultimate Fighting Championship data, enhancing in-play betting capabilities and offering dynamic micro markets and advanced visualizations to users. This expansion leverages Sportradar’s recent acquisition of IMG ARENA rights for P…

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Tonix Pharmaceuticals has dosed the first participant in a Phase 1 study evaluating TNX-1900, an intranasal potentiated oxytocin formulation, in healthy volunteers to assess its potential for treating migraine and craniofacial pain by inhibiting CGRP release through a novel pathway. The study uses advanced Laser Speckle Contrast Imaging (LSCI) to m…

Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit

Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit

Hyperion DeFi, Inc., the first U.S. publicly listed DeFi company on Hyperliquid, announced robust financial results for Q4 and FY 2025. The company exceeded Q4 guidance with 64% revenue growth and 87% growth in adjusted gross profit quarter-over-quarter. It operates five diversified DeFi business lines, including staking, validator commissions, yie…

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Therapeutics announced that the USPTO granted a composition of matter patent for AGMB-447, its inhaled lung-restricted ALK5 inhibitor in development for idiopathic pulmonary fibrosis (IPF). This patent protection extends in the U.S. through at least 2041, supporting the company's clinical-stage pipeline targeting fibrosis. AGMB-447 is curren…

Comstock Inc. Announces 2026 Annual Meeting

Comstock Inc. Announces 2026 Annual Meeting

Comstock Inc. announces its 2026 Annual Meeting of Shareholders to be held on May 28, 2026, in Reno, Nevada. The meeting will cover topics including Comstock Metals, strategic investments, and clean energy systems. The company emphasizes its focus on innovating technologies to recycle metals from end-of-life photovoltaics. The notice includes detai…

Hollister and Gigi Perez Collaborate to Reimagine “Good Riddance (Time of Your Life)” by Global Rock Band Green Day

Hollister and Gigi Perez Collaborate to Reimagine “Good Riddance (Time of Your Life)” by Global Rock Band Green Day

Abercrombie & Fitch's brand Hollister teams up with singer-songwriter Gigi Perez to release a reimagined version of Green Day's 'Good Riddance (Time of Your Life)' as part of a graduation season campaign. The initiative includes an original music video featuring young creatives and a new product collection themed around milestone moments, aimed at …

Ragnarok Origin Classic Official Launching in Korea, Taiwan, Hong Kong, Macau and Southeast Asia on March 26, 2026

Ragnarok Origin Classic Official Launching in Korea, Taiwan, Hong Kong, Macau and Southeast Asia on March 26, 2026

GRAVITY Co., Ltd. announced the official launch of Ragnarok Origin Classic, a multi-platform MMORPG available on PC and mobile devices, in Korea, Taiwan, Hong Kong, Macau, and Southeast Asia on March 26, 2026. The game features a monthly pass system and revamped combat design to enhance player engagement by focusing on skill and strategy, aiming to…

Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance

Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance

Lumexa Imaging announced robust preliminary financial results for Q4 and full year 2025, highlighted by revenue growth, improved adjusted EBITDA and margin expansion driven by advanced imaging volumes, new center openings, and key payer network returns. The company also reiterated its full-year 2026 guidance with expectations of continued growth an…